Drug Profile


Alternative Names: ACT-1; Granexin Gel

Latest Information Update: 16 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FirstString Research; Medical University of South Carolina
  • Class Eye disorder therapies; Peptide fragments; Skin disorder therapies
  • Mechanism of Action Gap junction modulators; Zonula occludens protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Diabetic foot ulcer; Leg ulcer; Radiation injuries; Scars
  • Phase II/III Radiodermatitis
  • Preclinical Age-related macular degeneration; Corneal injuries
  • No development reported Fibrosis; Spinal cord injuries

Most Recent Events

  • 01 May 2018 FirstString Research completes a phase I trial in Diabetic foot ulcer in USA (Topical) (NCT02652754)
  • 01 May 2018 FirstString Research completes a phase I trial in Leg ulcer in USA (Topical) (NCT02652572)
  • 05 Dec 2017 Preclinical development for Corneal injuries and Age-related-macular-degeneration is underway in USA (Ophthalmic, Drops) (FirstString Research Pipeline, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top